Wall Street brokerages forecast that Agilent Technologies Inc (NYSE:A) will report sales of $1.27 billion for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $1.26 billion to $1.28 billion. Agilent Technologies reported sales of $1.21 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 5%. The firm is expected to report its next quarterly earnings results on Monday, May 13th.
According to Zacks, analysts expect that Agilent Technologies will report full-year sales of $5.17 billion for the current year, with estimates ranging from $5.15 billion to $5.19 billion. For the next financial year, analysts anticipate that the company will post sales of $5.46 billion, with estimates ranging from $5.42 billion to $5.51 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Agilent Technologies.
Get Agilent Technologies alerts:Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.03. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The company’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.66 earnings per share.
A has been the subject of a number of research reports. Alembic Global Advisors cut shares of Agilent Technologies to a “hold” rating in a research note on Monday, December 31st. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Monday, January 21st. Needham & Company LLC assumed coverage on shares of Agilent Technologies in a research report on Wednesday, January 2nd. They set a “buy” rating and a $77.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Agilent Technologies to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 21st. Finally, Bank of America restated a “buy” rating and set a $87.00 price target (up from $78.00) on shares of Agilent Technologies in a research report on Thursday, February 21st. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $86.40.
Shares of A stock traded down $1.11 on Monday, reaching $80.13. 3,159,403 shares of the company were exchanged, compared to its average volume of 2,021,893. The stock has a market capitalization of $25.80 billion, a P/E ratio of 28.72, a P/E/G ratio of 2.18 and a beta of 1.33. The company has a quick ratio of 2.74, a current ratio of 3.39 and a debt-to-equity ratio of 0.36. Agilent Technologies has a 1 year low of $60.42 and a 1 year high of $81.76.
Agilent Technologies declared that its board has authorized a share repurchase program on Monday, November 19th that allows the company to buyback $1.75 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 8.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
In other Agilent Technologies news, insider Dominique Grau sold 8,902 shares of the business’s stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $77.00, for a total value of $685,454.00. Following the transaction, the insider now directly owns 103,387 shares in the company, valued at approximately $7,960,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Mark Doak sold 16,421 shares of the business’s stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $77.95, for a total transaction of $1,280,016.95. The disclosure for this sale can be found here. Insiders have sold 51,560 shares of company stock worth $3,956,598 over the last 90 days.
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc boosted its holdings in Agilent Technologies by 0.8% in the 3rd quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock valued at $1,703,929,000 after purchasing an additional 194,607 shares during the last quarter. OppenheimerFunds Inc. raised its stake in shares of Agilent Technologies by 12.5% in the 3rd quarter. OppenheimerFunds Inc. now owns 8,590,725 shares of the medical research company’s stock valued at $605,989,000 after acquiring an additional 954,104 shares during the period. American Century Companies Inc. raised its stake in shares of Agilent Technologies by 16.9% in the 3rd quarter. American Century Companies Inc. now owns 5,359,933 shares of the medical research company’s stock valued at $378,090,000 after acquiring an additional 774,771 shares during the period. Geode Capital Management LLC raised its stake in shares of Agilent Technologies by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock valued at $285,139,000 after acquiring an additional 285,330 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Agilent Technologies by 2.0% in the 4th quarter. Northern Trust Corp now owns 3,807,998 shares of the medical research company’s stock valued at $256,888,000 after acquiring an additional 75,416 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Further Reading: What is Depreciation?
Get a free copy of the Zacks research report on Agilent Technologies (A)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment